Needham Reiterates Buy on Stoke Therapeutics, Maintains $22 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has reiterated a Buy rating on Stoke Therapeutics (NASDAQ:STOK) and maintained a $22 price target.
August 08, 2024 | 10:40 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Needham analyst Joseph Stringer has reiterated a Buy rating on Stoke Therapeutics and maintained a $22 price target.
The reiteration of a Buy rating and maintenance of a $22 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100